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ABSTRACT
Introduction: Sepsis is an acute illness resulting from
infection and the host immune response. Early
identification of individuals at risk of developing life-
threatening severe sepsis could enable early triage and
treatment, and improve outcomes. Currently available
biomarkers have poor predictive value for predicting
subsequent clinical course in patients with suspected
infection. Circulating leucocytes provide readily
accessible tissues that reflect many aspects of the
complex immune responses described in sepsis. We
hypothesise that measuring cellular markers of
immune responses by flow cytometry will enable early
identification of infected patients at risk of adverse
outcomes. We aim to characterise leucocyte surface
markers (biomarkers) and their abnormalities in a
population of patients presenting to the hospital
emergency department with suspected sepsis, and
explore their ability to predict subsequent clinical
course.
Methods and analysis: We will conduct a
prospective, multicentre, clinical, exploratory, cohort
observational study. To answer our study question, 3
patient populations will be studied. First, patients with
suspected sepsis from the emergency department
(n=300). To assess performance characteristics of
potential tests, critically ill patients with established
sepsis, and age and gender matched patients without
suspicion of infection requiring hospital admission (both
n=100) will be recruited as comparator populations. In all
3 groups, we plan to assess circulating biomarker
profiles using flow cytometry. We will select candidate
biomarkers by cross-cohort comparison, and then
explore their predictive value for clinical outcomes within
the cohort with suspected sepsis.
Ethics and dissemination: The study will be carried
out based on the principles in the Declaration of Helsinki
and the International Conference on Harmonisation Good
Clinical Practice. Ethics approval has been granted from
the Scotland A Research Ethics Committee (REC) and
Oxford C REC. On conclusion of this study, the results
will be disseminated via peer-reviewed journals.
Trial registration number: NCT02188992; Pre-results.
INTRODUCTION
Acute illness secondary to suspected or
proven infections account for between 6 and
16% of emergency department (ED) cases.1–3
Approximately half of these patients will have
sepsis,2 3 defined as infection with signs of
systemic inflammation.4 5 It has been esti-
mated that around 25% of patients with
sepsis syndrome develop severe sepsis (sepsis
with organ failure),1 6 and 5–10% septic
shock (sepsis with cardiovascular failure).1
Strengths and limitations of this study
▪ This multi-centre study aims to address an
important question in the field of sepsis in the
development of a novel predictive biomarker,
where our current strategies to identify the
deteriorating patient early are poor.
▪ Designed by clinicians in conjunction with
immunologists, statisticians, flow cytometry
technologists, with industry collaboration, to
ensure a robust study design.
▪ Multiple cohort groups for comparison of clinical
and immune phenotypes.
▪ Derivation study – any findings will have to be
further validated.
▪ Complex study procedures, due to the involve-
ment of clinical and laboratory teams over mul-
tiple sites, which will need to be streamlined to
develop a clinically useful test for non-tertiary
non-urban medical settings.
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Mortality increases progressively with these syndromes,
with septic shock associated with a 40% mortality.7
Predicting patients with sepsis who are likely to deteri-
orate is clinically useful, because it could assist clinical
triage and decision-making, and result in earlier inter-
ventions to prevent organ failure and morbidity.
Circulating leucocytes mediate many aspects of the
inflammatory response to infection, are easily accessible
through blood sampling, and are a potential target for
biomarker discovery for predictors of subsequent clinical
deterioration.8 Most previous research has focused on
soluble mediators, or small studies of immune cell func-
tion in a range of sepsis populations.9–13 We hypothe-
sised that measuring leucocyte cell surface markers
(hereafter ‘leucocyte biomarkers’) of immune responses
by flow cytometry will enable the early identification
of infected patients at risk of development of
sepsis-associated organ dysfunction or death. We also
hypothesised that leucocyte biomarkers will have better
discriminant ability than existing soluble inflammation
markers that are widely used in clinical practice, such as
C reactive protein (CRP) and procalcitonin (PCT). We
describe the protocol for a discovery study to explore
whether leucocyte biomarkers have potential predictive
value for relevant clinical outcomes in patients with
sepsis presenting to the ED.
Rationale for study
Cells of the innate immune system (monocytes, granulo-
cytes and dendritic cells) and cells of the lymphocyte
lineage (such as T cells, B cells and natural killer cells)
have all been reported to have major abnormalities in
animal models of sepsis and in selected human studies.8
Broadly, neutrophil life span is prolonged, with imma-
ture forms of neutrophils appearing in the peripheral
circulation. Monocyte function is impaired, in particular
the cell’s ability to present antigens alongside downregu-
lation of HLA-DR expression on cell surfaces. In patients
with sepsis, lymphocytes are activated, with concurrent
increase in inhibitory cell surface molecules and inhibi-
tory cell populations, all of which have been associated
with increased risk of secondary infections and death.8
However, most studies have sampled a critically ill sepsis
population to characterise these abnormalities; these
patients typically have established organ dysfunction and
are self-selected as patients developing severe disease.
Conceptually, infection leading to a host response result-
ing in sepsis is a temporal event.14 For these biological
processes to be potentially useful as predictive and/or
diagnostic tests, they need to be associated with the
development of subsequent severe disease in a patient
population with acute illness and infection when mea-
sured at an earlier time point in the illness trajectory.
Specifically, the predictive value for subsequent clinical
deterioration is most relevant before significant organ
dysfunction has developed.
A potential approach to exploring the association
between leucocyte biomarkers and clinical outcomes is
to compare the leucocyte phenotypes in a population
fulfilling clinical criteria for sepsis but without severe
organ dysfunction with a population of patients with
established severe sepsis and with matched healthy
control populations. This approach has been widely
used to provide preliminary evidence for associations
between biomarkers and disease conditions, but a major
weakness is that patients come from different popula-
tions. The gold standard approach to biomarker and
diagnostic test discovery is to explore predictive value
within a single population of interest, in which the event
of interest occurs in a subgroup.15 For sepsis research,
the optimum approach is to recruit from a well-defined
patient cohort, and follow these cases to ascertain which
develop organ dysfunction and/or critical illness.
A diagnostic test that predicts deterioration could have
clinical value in a population in whom the pretest prob-
ability for progressing to severe sepsis is low, as it may
influence the intensity of therapy, monitoring and subse-
quent placement in the hospital (eg, early admission to
critical care). Patients presenting to the ED represent a
high volume population who frequently fulfil sepsis cri-
teria, have a low rate of subsequent development of sig-
nificant organ dysfunction and in whom triage decisions
can be difficult. The goal of the Early PREdiction of
Severe Sepsis (ExPRES-Sepsis) study is to identify poten-
tial leucocyte biomarkers with clinically relevant predict-
ive value in an ED population. Our approach is to
characterise the expression of leucocyte surface markers
of immune response by flow cytometry in three popula-
tions: patients presenting to the ED with suspected
sepsis, patients with established severe sepsis in the
intensive care unit (ICU) and an age/gender matched
non-septic control population in the ED. These three
cohorts will be used to select promising leucocyte bio-
markers that may have predictive value for subsequent
clinical deterioration within the ED cohort. Within
the ED suspected sepsis cohort, we will follow patients’
clinical course to study the predictive value of leucocyte
biomarkers for subsequent development of organ dys-
function and other relevant clinical outcomes. We
hypothesise that some immune/inflammatory cell sur-
face markers, measured in a population of patients pre-
senting to hospital with sepsis, will have predictive value
for the subsequent development of clinically severe
disease characterised by the development or worsening
of acute organ dysfunction.
Aims
1. To characterise the expression of leucocyte bio-
marker abnormalities by flow cytometry in patients
presenting with suspected infection, non-infective
acute illness and critically ill patients with severe
sepsis;
2. To test the ability of these markers to predict clinical
deterioration in patients with suspected infection;
3. To test the association between these biomarkers and
subsequently confirmed infection;
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4. To compare the performance of promising leucocyte
biomarkers with established soluble markers of infec-
tion (CRP and PCT).
METHODS
Study design
ExPRES-Sepsis is a prospective, multicentre, exploratory,
cohort observational study.
Study sites
The study will recruit from four sites in the UK: Royal
Infirmary of Edinburgh (Edinburgh, Scotland, UK);
Western General Hospital (Edinburgh, Scotland, UK);
Royal Victoria Infirmary (Newcastle, England, UK); St
Thomas’ Hospital (London, England, UK).
Definitions
Sepsis is defined as a systemic inflammatory response
syndrome (SIRS) due to infection.4 The criteria for SIRS
are two or more of the following four physiological
responses to a clinical insult: (1) temperature >38°C or
<36°C, (2) heart rate >90 bpm, (3) respiratory rate >20
breaths per minute, or arterial carbon dioxide tension
<32 mm Hg (equivalent to 4.3 kPa), (4) white cell count
>11 or <4 (×109 cells), or 10% immature (band) forms.4
Severe sepsis is sepsis with one of organ dysfunction,
hypoperfusion or hypotension.4 Septic shock is the pres-
ence of hypotension due to sepsis which persists despite
adequate fluid resuscitation.4 Critical care is defined as
an ICU or high dependency unit as used in the UK.16 17
Diagnosis of sepsis, severe sepsis and septic shock
In the ExPRES-Sepsis study, we will diagnose sepsis in a
patient where they meet at least two out of four of the
SIRS criteria, plus one of the following: (1) suspected
infection being investigated with blood cultures and/or
treated with antibiotics, (2) clinically confirmed infec-
tion (derived from Horan et al,18 see online supplemen-
tary appendix B) or (3) microbiologically confirmed
infection (see online supplementary appendix B).
We will diagnose severe sepsis as: (1) the patient has
been diagnosed with sepsis, and (2) the patient has
organ dysfunction. Organ dysfunction will be measured
by the Sepsis-related Organ Failure Assessment (SOFA)
score.19
Septic shock will be diagnosed in critical care units,
using modified PROWESS-SHOCK trial criteria, where:
(1) the patient has been diagnosed with sepsis; (2) the
patient has required vasopressors for 4 hours, consisting
of either (A) norepinephrine at >5 μg/min, (B) epi-
nephrine at >5 μg/min or (c) vasopressin at >0.03 units/
min; and (3) evidence of organ hypoperfusion.20 Organ
hypoperfusion is defined as one of the following: (1)
base excess of ≥5 mmol/L, (2) bicarbonate of
<18 mmol/L, (3) lactate of >2.5 mmol/L, (4) urine
output of <0.5 mL/kg/hour, (5) 50% increase in cre-
atinine from baseline, (6) hepatic dysfunction alanine
transaminase/aspartate transaminase >500 IU/L or (7)
bilirubin >2 mg/dL (34.2 μmol/L).20 21
Septic shock will be diagnosed in non-critical care set-
tings where the patient meets ALL of the following cri-
teria: (1) sustained systolic hypotension (systolic blood
pressure <90 mm Hg for ≥4 hours), (2) despite
adequate fluid resuscitation (≥30 mL/kg of any intra-
venous fluid) and (3) during the 8 hours following start
of the episode of systolic hypotension.20
Patient cohorts
We will recruit three distinct patient cohorts:
Cohort 1: patients presenting to hospital with suspected
infection with a systemic inflammation (sepsis; discovery
cohort).
Cohort 2: hospitalised patients with community-acquired
severe sepsis requiring treatment in critical care (true-
positive cohort).
Cohort 3: patients presenting with no suspicion of
infection or systemic inflammation, needing hospitalisa-
tion (‘non-sepsis comparison population’).
Sample size
Cohorts 1 and 2: The sample size for cohorts 1 and 2 was
calculated on a combination of: (1) an expected event
rate of 5–10% in cohort 1 of developing the outcome of
interest (severe sepsis and/or critical care admission),
(2) confidence interval (CI) widths for positive and
negative predictive values (PPV and NPV, respectively)
and (3) the number of ‘true positives’ required in
cohort 2.
In a cohort 1 sample of 300, we expect 15–30 events
of interest. With 100 true positives in cohort 2, the
numbers of patients with severe sepsis and/or critical
care admission in cohorts 1 and 2 (400 patients overall)
combined will be 115–130—around 25–30%. Assuming
a range of PPV/NPV performance from 50% to 90%,
the CI widths would range from ±4.6% to ±9.8% for
PPV, and ±3.4% to ±6.3% for NPV. We considered this
level of precision acceptable for an exploratory deriv-
ation study.
Cohort 3: The non-sepsis population (n=100) will be
used as a comparator group to explore candidate
markers that have potential predictive value in the popu-
lation of interest, and was chosen to be equivalent in
size to cohort 2. Determining leucocyte biomarkers with
little variance in non-septic patients will be an important
property in relation to potential utility for detecting
sepsis. An a priori-defined sampling strategy was
designed, starting midway through the recruitment to
cohort 1, to ensure the age and gender profile of cohort
3 matches cohort 1 (table 1).
A detailed trial analysis plan will be agreed before the
database is locked, and will take into account the clinical
characteristics of the populations enrolled in the study,
especially event rates and final numbers recruited (see
below).
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Screening procedure
Screening of consecutive patients will be performed by
qualified individuals designated by the local principal
investigator (PI). A screening log will be maintained at
each site to capture reasons for non-inclusion of eligible
patients.
Inclusion criteria
Cohort 1
Age ≥16 years (≥18 years in England), (2) SIRS criteria
met, (3) clinical suspicion of sepsis (blood cultures and/
or other samples taken for microbial culture, or antibio-
tics started by clinical team), (4) no clinical suspicion of
severe sepsis or septic shock at the time of enrolment
and (5) enrolled within 12 hours of hospital (ED)
presentation.
Cohort 2
Age ≥16 years (≥18 years in England), (2) SIRS criteria
met, (3) clinical suspicion of sepsis (blood cultures and/
or other samples taken for microbial culture, or antibio-
tics started by clinical team), (4) severity of sepsis requir-
ing critical care admission (based on decision of caring
clinical teams), (5) enrolled within 72 hours of hospital
admission and (6) not enrolled into cohort 1 of
ExPRES-Sepsis.
Cohort 3
Age ≥16 years (≥18 years in England), (2) does not
meet SIRS criteria, (3) no clinical suspicion of sepsis
(blood cultures and/or other samples NOT taken for
microbial culture, and antibiotics NOT started by clinical
team), (4) patient expected to be admitted to hospital,
(5) patient NOT expected to die during hospital
admission.
Exclusion criteria (for all cohorts)
Exclusions were chosen to ensure conditions that
provoke a sterile inflammatory response or lead to
immune dysfunction did not act as confounders during
flow cytometry analysis. Patients who would not be
actively treated were also excluded.
The exclusion criteria are any of: (1) acute pancrea-
titis, (2) haematological malignancy, (3) recent chemo-
therapy (past 2 weeks), (4) myelodysplastic syndromes,
(5) known neutropenia, (6) HIV infection, (7) viral
hepatitis infection, (8) pregnancy, (9) blood transfusion
>4 units in past week, (10) oral corticosteroids for
>24 hours prior to enrolment, (11) decision not for
active therapy/for palliative care at admission and (12)
inability to consent the patient.
Consent
Informed consent is obtained from the patient, or from
their relatives when they are incapacitated due to sepsis,
for recruitment to ExPRES-Sepsis by trial research
nurses. If a patient regains capacity, their personal
consent to remain in the study is sought.
Clinical management of patients in the study
Clinical management of patients in this study will
remain entirely at the discretion of the treating clinician:
no treatment alterations will occur as a result of study
participation. Data will be collected to benchmark clin-
ical management against national standards for sepsis
management, the ‘sepsis six’, for cohort 1.22 23
Study assessments
Recruiting staff will be blinded to the results of labora-
tory analysis; conversely laboratory staff are blinded to
clinical data.
Blood sampling
Up to 10 mL of blood will be taken at each sampling
point (table 2) for flow cytometric analysis of leucocyte
biomarker expression. Where possible, this will be at
time of venous access insertion or sampling for clinical
indications. The sequential sampling within cohort 1 will
be completed whenever possible for exploratory analyses
of leucocyte biomarkers changes over time. Sequential
sampling will only occur when the patient remains in
hospital, the patient agrees and it is technically feasible.
Further handling of blood samples
Leucocyte surface markers of immune responses will be
measured using flow cytometric analysis within 4 hours
of sample acquisition. Blood is held at 4°C for process-
ing. Excess blood not used for flow cytometric analysis
will be frozen and stored as blood plasma for future ana-
lysis, including CRP and PCT.
Table 1 Cohort 3 age and gender matching matrix
Age range
Target
number of
male patient
Target
number of
female
patient
Total
number of
patients
Age≥85 4 7 11
75≤age<85 6 11 17
65≤age<75 14 13 27
55≤age<65 4 8 12
45≤age<55 6 3 9
35≤age<45 6 5 11
25≤age<35 6 3 9
16≤age<25 2 2 4
Table 2 Early PREdiction of Severe Sepsis
(ExPRES-Sepsis) sampling schedule
Enrolment 24 hours 72 hours
Cohort 1 ✓ ✓ ✓
Cohort 2 ✓
Cohort 3 ✓
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Flow cytometry data collection
Leucocyte biomarker expression will be recorded using
antibody staining and measurement by flow cytometry.24
Antibodies are supplied by Becton Dickinson
Biosciences (BDB). All sites use antibodies from the
same batch. Antibodies selected for cell surface staining
have either shown previous association with differential
expression in inflammation, and therefore noted to be
of potential in the development of a clinical test, or are
used to select leucocyte subtypes of interest. Our aim is
to explore a wide range of potentially relevant cell
surface biomarkers on different immune cell types and
subtypes. Specific assays will be developed for the
purpose of the study, and agreed prior to undertaking
the analyses in real time during the clinical study. The
exact biomarkers chosen are not detailed in this proto-
col manuscript, in part because of IP issues. The final
biomarker panel selected, their reliability and the per-
formance of all those evaluated will be included in the
main manuscript (including those rejected due to poor
reliability).
All sites have standardised on the same platform, the
FACSCanto II (BDB, San Jose, California, USA), for flow
cytometric analysis of samples. Machines will be standar-
dised by monthly matching of target values using a
common batch of BDB Cytometry Setup and Tracking
beads, and daily internal quality control using these
beads. Staining, data capture and storage will be con-
ducted in accordance with a single study standard oper-
ating procedure.
Flow cytometry data will be held centrally. Final ana-
lysis will be conducted using a single analysis platform,
VenturiOne (Applied Cytometry, Sheffield, UK).
Clinical data collection
Patients in cohort 1 will be followed to record their sub-
sequent clinical status and specifically for the develop-
ment of organ dysfunction. Patients in cohorts 2 and 3
will only have data collected at the time of blood
sampling.
The following data will be collected from each patient:
demographics (age, gender, functional comorbidity
index25); Acute Physiology and Chronic Health
Evaluation (APACHE) II score on study entry; SOFA
score at enrolment, 24 and 72 hours; standardised early
warning system (SEWS) score at enrolment, 24 and
72 hours; clinical data (admission diagnosis, length of
stay, maximum level of care); treatment data (antibiotics,
use of vasopressors, volume of fluid administered during
first 12 hours, recording of critical care interventions);
final diagnosis; infection data—including confirmation
or refutation of diagnosis of infection (see online sup-
plementary appendix B), source of infection and results
of microbial cultures; need for source control procedure
(surgical operation, percutaneous drainage, endoscopic
treatment); ceiling of care decisions (eg, anticipatory
care planning against cardiopulmonary resuscitation,26
patient judged not suitable for critical care); and
conventional laboratory test results taken as part of
standard care.
ANALYSIS PLAN
Analysis of the data set in ExPRES-Sepsis will follow an
iterative process to test, eliminate and validate potential
biomarkers and outcomes of interest (figure 1). The
flow cytometry and clinical expertise within the investiga-
tor group will allow us to optimise the biomarkers that
we will select to explore associations with our outcomes
of interest in the final stages of analysis.
Stage 1: reliability and optimisation
The first stage of analysis will use the raw flow cytometry
data, without any matching clinical data, from all
cohorts to explore whether the flow cytometric readings
(gating) of each marker are reproducible.27
Interobserver and intraobserver reliability studies will be
conducted with three expert readers of the data. Fifty
data files per reader will be analysed to determine inter-
observer agreement, with 13 files for intraobserver
agreement.28 After an initial reliability study, a learning
and optimisation stage will occur using expert meetings
to refine gating strategies in problematic markers to
ensure we do not incorrectly reject markers. Thereafter,
a second reliability study, using the same sample size,
will be conducted. The results will be reviewed at a
further meeting of the research team, including flow
cytometry experts, to select markers that show robust
reliability to take forward for further analysis.
Stage 2: discovery
Stage 2 has two parallel processes of discovery—bio-
logical and clinical. The two data sets (laboratory and
clinical) will continue to be kept separate, with research-
ers blinded to the matched immune and clinical pheno-
types of the patients.
Biological discovery
Leucocyte biomarker expression will be compared across
all three cohorts, without matching clinical data, to
rationalise markers that may be associated with the clin-
ical phenotype of interest, namely severe sepsis with (or
without) organ dysfunction. Specifically, we will identify
potential leucocyte biomarkers that show differential
expression between the three clinical phenotypes. A
further expert meeting will take place to review these
results in combination with relevant literature relating to
each of the leucocyte biomarkers. At this meeting, the
reliability data, detailed review of existing literature,
results from the cross-cohort analysis of the study and
expert consensus will determine the selection of biomar-
kers to be used for further analysis (see below). The
rationale and justification for all inclusion and rejection
of candidate biomarkers will be described and documen-
ted at this time. The aim will be to select leucocyte bio-
markers that have sufficient measurement reliability to
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be used in clinical practice and show promise for dis-
criminating between the study cohorts, particularly
between cohort 2 (established severe sepsis) and cohort
3 (matched non-septic controls).
Definition of clinical outcomes of interest
This phase will be limited to cohort 1, the population of
interest in whom we aim to predict outcomes. Several
outcomes have been chosen. We justify this by the
exploratory nature of the study, and in order to include
clinical phenotypes of differing severity based on organ
dysfunction and clinical destination at 24–72 hours.
At the time of designing the study, we proposed a
primary outcome of septic shock and expected that 5–
10% of enrolled patients would develop this during
follow-up. During the conduct of the study, in May to
June 2015, an interim analysis of the clinical data was
performed to explore the event rate for septic shock.
This indicated that rates were significantly lower than
anticipated prior to the study (<5%). In July 2015, the
decision was made to change the main outcome to the
Figure 1 ExPRES-Sepsis analysis flow chart.
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development of organ dysfunction during the 24–
72 hours following recruitment. This was considered
clinically relevant because it is associated with signifi-
cantly increased mortality and the need for critical care
admission in many cases. A diagnostic test that could
predict this outcome at the time of assessment in the
ED would have potential clinical value. The final deci-
sion regarding the cut-off level of organ failure severity
for the analyses was made after the publication of the
revised international sepsis definitions in March 2016.29
These suggested a SOFA score increase of ≥2 as the
cut-off for defining sepsis, with the assumption that the
preacute illness SOFA was 0 unless clear evidence of
chronic organ dysfunction contributing to SOFA points
was available. We therefore chose a SOFA score of ≥2 as
main outcome, and a more severe value of ≥4 as a sec-
ondary outcome.
The outcomes of interest that will be used in cohort 1
to explore the potential predictive value of the novel
leucocyte biomarkers will be:
Primary measure
Sepsis-related Organ Failure Assessment (SOFA) score
≥2 at 24 or 72 hours or both following presentation to
hospital.
Secondary measures (in order of priority)
1. Critical care admission, or death, within 72 hours of
presentation;
2. Organ dysfunction (SOFA≥4) at 24 or 72 hours or
both following presentation to hospital;
3. Discharge home within 72 hours;
4. Discharge to home, or in hospital with no organ
failure, within 72 hours of presentation;
5. Death from sepsis;
6. Length of hospital stay;
7. Confirmed infection (clinical and/or microbiological
confirmation);
8. Microbiologically proven sepsis;
9. Development of septic shock.
Justification and rationale for outcomes of interest
Higher levels of organ dysfunction, as assessed using
SOFA score,19 are associated with higher mortality, mor-
bidity and illness costs. Observational studies show that
in critical care populations, there is 9% mortality rate in
patients with no organ dysfunction, compared with 22%
and 83%, respectively, in patients with one and four
organ failures.30 It therefore can be considered a patho-
physiological surrogate for ‘critical care admission
within 72 hours’; however, the SOFA score will provide
more stratified information on the patients’ condition,
and is consistent with the new definitions of sepsis that
emphasise the prognostic importance of organ failure.29
The need for critical care admission within 72 hours
of first presentation to hospital is a relevant clinical
outcome that identifies patients requiring higher inten-
sity of care, who may benefit from ‘early’ clinical
interventions for sepsis and/or early admission for moni-
toring. Conversely, discharge to home within 72 hours of
first presentation to hospital indicates an outcome indi-
cative of low illness severity. These two outcomes repre-
sent an important dichotomy in the population when
reviewed in the ED. A test that could change the pretest
to post-test probability of both outcomes has potential
clinical utility as a decision-making tool. A further
outcome of discharge to home within 72 hours, or in
hospital with no organ failure at 72 hours, is similar to
outcome 2, but will also identify the group of patients
who would be medically suitable for discharge home,
but are prevented from doing so for social or other
reasons.
Prediction of microbiologically positive infection lends
itself to a clinically useful test. However, this outcome is
exploratory as it has been previously shown that many
patients with sepsis have negative blood cultures, with
only 30–40% positive in severe sepsis/septic
shock.11 31 32
Stage 3: biomarker exploration
Clinical data will be linked to leucocyte biomarker data
in this stage of analysis. The leucocyte biomarkers
selected in stage 2 will be analysed for their ability to
predict the development of the clinical outcomes of
interest using receiver operator characteristic (ROC)
curves to determine optimum cut-off points. The PPV,
NPV, positive and negative likelihood ratio, sensitivity,
specificity and area under ROC curve will also be calcu-
lated for each marker. Ninety-five per cent CIs will be
reported for all measures of predictive accuracy.
Comparative performance characteristics for tests used
in current routine management of the patients, namely
CRP and PCT, will also be calculated.
Stage 4: clinical optimisation
The biomarker performance data will be examined, and
further discussed with experts within the research group
and external independent experts, to assess the poten-
tial clinical utility for the leucocyte biomarkers. At this
stage, the potential for combining biomarkers to
increase and optimise predictive ability will be explored.
ETHICS, REGULATIONS AND GOVERNANCE
Study management
The study is managed by the Edinburgh Clinical Trials
Unit (ECTU) and the Edinburgh Critical Care Research
Group at the University of Edinburgh, Scotland. The study
sponsor and funders will not have any decision making
authority in the conduct of this study once approved.
Sponsorship
The study is co-sponsored by University of Edinburgh
and National Health Service (NHS) Lothian.
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Duration and current status of study
The study is planned to run for 3 years. The first patient
was recruited in January 2014. At the current time (25
January 2016) recruitment to each cohort is ongoing. The
expected end date for recruitment is 31 January 2016. We
expect to have completed our primary data analysis plan
with a view to dissemination of results by August 2016.
Ethical and regulatory approvals
The study will be conducted in accordance with the
ethical principles that have their origin in the
Declaration of Helsinki, and the International
Conference on Harmonisation Good Clinical Practice.33
The CI, site PIs and clinical research staff have com-
pleted the relevant training with up-to-date certification.
Local research and development approval has been
granted for each study site. The study has been regis-
tered with the UK National Institute for Health
Research (NIHR) Clinical Research Portfolio.
Dissemination
The study will be reported according to the STARD
guidance for reporting diagnostic accuracy studies.34
The findings will be disseminated via peer-reviewed pub-
lications, and at national and international meetings. A
lay person’s summary of the principal findings will be
sent on request to all patients involved in the study. In
addition, the most significant results will be communi-
cated to the public through press releases.
Protocol compliance
The investigators will conduct the study in compliance
with the protocol given favourable opinion by the
Research Ethics Committee (REC). Protocol changes will
require REC favourable opinion prior to implementation,
except when modification is needed to eliminate imme-
diate hazards to patients. The ECTU in collaboration
with the Sponsor will submit all protocol modifications to
the REC for review in accordance with the governing reg-
ulations. Protocol compliance will be monitored by the
trial manager who will ensure that the trial protocol is
adhered to and that necessary paperwork (case report
form, patient consent) are being completed appropri-
ately. Any deviations from the protocol will be fully docu-
mented in source documentation and case report form.
Patient confidentiality
In order to maintain confidentiality, all case report
forms, stored samples and study reports will identify
patients by the assigned unique study identifier number
only. The only link between the patient’s identity and
the unique study identifier number will be held securely
at the relevant study site.
SUMMARY
The ExPRES-Sepsis study is a large multicentre explora-
tory study to identify potential novel leucocyte biomar-
kers that predict subsequent clinical deterioration in
sepsis in patients early in their presentation to hospital.
The measurement of leucocyte surface markers is a
promising strategy for a predictive test. The recruitment
and analysis plan ensures we have a robust biomarker set
for prediction of clinically relevant outcomes. If we find
a positive association with clinical interest, further valid-
ation of these markers could lead to the development of
a clinically useful early test in sepsis.
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